MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib

Nucleic Acids Research

Volumn 42, Issue 16, 2014, Pages 10433-10447

  Wirth, Matthias ^a   Stojanovic, Natasa ^a   Christian, Jan ^b   Paul, Mariel C ^a   Stauber, Roland H ^c   Schmid, Roland M ^a   Häcker, Georg ^d   Krämer, Oliver H ^c   Saur, Dieter ^a   Schneider, Günter ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; BIM PROTEIN; BORTEZOMIB; EARLY GROWTH RESPONSE FACTOR 1; HISTONE H3; LYSINE; MESSENGER RNA; MYC PROTEIN; PROTEASOME; PROTEIN NOXA; PROTEIN P53; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; BORONIC ACID DERIVATIVE; MEMBRANE PROTEIN; ONCOPROTEIN; PMAIP1 PROTEIN, MOUSE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PYRAZINE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARF GENE; ARTICLE; BIM GENE; BINDING SITE; CELL DEATH; CELL STRESS; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NOXA GENE; PANCREAS CANCER; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; ANIMAL; CELL CULTURE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; BORONIC ACIDS; BORTEZOMIB; CELL LINE, TUMOR; CELLS, CULTURED; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, P53; MEMBRANE PROTEINS; MICE; PROMOTER REGIONS, GENETIC; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES; TRANSCRIPTION, GENETIC;

EID: 84921334202     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gku763     Document Type: Article

References (81)

1. Strasser, A., Cory, S. and Adams, J.M. (2011) Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J., 30, 3667-3683.
2. Eilers, M. and Eisenman, R.N. (2008) Myc's broad reach. Genes Dev., 22, 2755-2766.
3. Pelengaris, S., Khan, M. and Evan, G. (2002) c-MYC: more than just a matter of life and death. Nat. Rev. Cancer, 2, 764-776.
4. Nilsson, J.A. and Cleveland, J.L. (2003) Myc pathways provoking cell suicide and cancer. Oncogene, 22, 9007-9021.
5. Larsson, L.G. and Henriksson, M.A. (2010) The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp. Cell Res., 316, 1429-1437.
6. Meyer, N. and Penn, L.Z. (2008) Reflecting on 25 years with MYC. Nat. Rev. Cancer, 8, 976-990.
7. Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J. and Roussel, M.F. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev., 12, 2424-2433.
8. Schneider, G., Henrich, A., Greiner, G., Wolf, V., Lovas, A., Wieczorek, M., Wagner, T., Reichardt, S., von Werder, A., Schmid, R.M. et al. (2010) Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene, 29, 2795-2806.
9. Conradt, L., Godl, K., Schaab, C., Tebbe, A., Eser, S., Diersch, S., Michalski, C.W., Kleeff, J., Schnieke, A., Schmid, R.M. et al. (2011) Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia, 13, 1026-1034.
10. Weber, A., Kirejczyk, Z., Potthoff, S., Ploner, C. and Hacker, G. (2009) Endogenous noxa determines the strong proapoptotic synergism of the BH3-mimetic ABT-737 with chemotherapeutic agents in human melanoma cells. Transl. Oncol., 2, 73-83.
11. Trumpp, A., Refaeli, Y., Oskarsson, T., Gasser, S., Murphy, M., Martin, G.R. and Bishop, J.M. (2001) c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature, 414, 768-773.
12. Conradt, L., Henrich, A., Wirth, M., Reichert, M., Lesina, M., Algul, H., Schmid, R.M., Kramer, O.H., Saur, D. and Schneider, G. (2013) Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Int. J. Cancer, 132, 2248-2257.
13. von Burstin, J., Eser, S., Paul, M.C., Seidler, B., Brandl, M., Messer, M., von Werder, A., Schmidt, A., Mages, J., Pagel, P. et al. (2009) E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology, 137, 361-371, 371, e1-e5.
14. Hingorani, S.R., Petricoin, E.F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M.A., Ross, S., Conrads, T.P., Veenstra, T.D., Hitt, B.A. et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4, 437-450.
15. Nakhai, H., Sel, S., Favor, J., Mendoza-Torres, L., Paulsen, F., Duncker, G.I. and Schmid, R.M. (2007) Ptf1a is essential for the differentiation of GABAergic and glycinergic amacrine cells and horizontal cells in the mouse retina. Development, 134, 1151-1160.
16. Seidler, B., Schmidt, A., Mayr, U., Nakhai, H., Schmid, R.M., Schneider, G. and Saur, D. (2008) A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc. Natl Acad. Sci. USA, 105, 10137-10142.
17. Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M. and Berns, A. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet., 29, 418-425.
18. Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S. and DePinho, R.A. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev., 17, 3112-3126.
19. Yu, J., de Belle, I., Liang, H. and Adamson, E.D. (2004) Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Mol. Cell, 15, 83-94.
20. Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelstein, D., Qu, C., Pounds, S., Ellison, D.W. et al. (2012) A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell, 21, 168-180.
21. Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W.C., Stukenberg, P.T., Shenolikar, S., Uchida, T. et al. (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol., 6, 308-318.
22. Wirth, M., Fritsche, P., Stojanovic, N., Brandl, M., Jaeckel, S., Schmid, R.M., Saur, D. and Schneider, G. (2011) A simple and cost-effective method to transfect small interfering RNAs into pancreatic cancer cell lines using polyethylenimine. Pancreas, 40, 144-150.
23. Labisso, W.L., Wirth, M., Stojanovic, N., Stauber, R.H., Schnieke, A., Schmid, R.M., Kramer, O.H., Saur, D. and Schneider, G. (2012) MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle, 11, 1593-1602.
24. Brandl, M., Seidler, B., Haller, F., Adamski, J., Schmid, R.M., Saur, D. and Schneider, G. (2010) IKK(alpha) controls canonical TGF(ss)-SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in panc1 cells. J. Cell Sci., 123, 4231-4239.
25. Klockenbusch, C. and Kast, J. (2010) Optimization of formaldehyde cross-linking for protein interaction analysis of non-tagged integrin beta1. J. Biomed. Biotechnol., 2010, 927585.
26. Diersch, S., Wenzel, P., Szameitat, M., Eser, P., Paul, M.C., Seidler, B., Eser, S., Messer, M., Reichert, M., Pagel, P. et al. (2013) Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget, 4, 277-288.
27. Metivier, R., Penot, G., Hubner, M.R., Reid, G., Brand, H., Kos, M. and Gannon, F. (2003) Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell, 115, 751-763.
28. Rice, P., Longden, I. and Bleasby, A. (2000) EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet., 16, 276-277.
29. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S. et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA, 102, 15545-15550.
30. Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C. et al. (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res., 41, D808-D815.
31. Jensen, L.J., Kuhn, M., Stark, M., Chaffron, S., Creevey, C., Muller, J., Doerks, T., Julien, P., Roth, A., Simonovic, M. et al. (2009) STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res., 37, D412-D416.
32. Fennell, D.A., Chacko, A. and Mutti, L. (2008) BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene, 27, 1189-1197.
33. Nikiforov, M.A., Riblett, M., Tang, W.H., Gratchouck, V., Zhuang, D., Fernandez, Y., Verhaegen, M., Varambally, S., Chinnaiyan, A.M., Jakubowiak, A.J. et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc. Natl. Acad. Sci. USA, 104, 19488-19493.
34. Qi, Y., Gregory, M.A., Li, Z., Brousal, J.P., West, K. and Hann, S.R. (2004) p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature, 431, 712-717.
35. Datta, A., Nag, A., Pan, W., Hay, N., Gartel, A.L., Colamonici, O., Mori, Y. and Raychaudhuri, P. (2004) Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J. Biol. Chem., 279, 36698-36707.
36. Boone, D.N., Qi, Y., Li, Z. and Hann, S.R. (2011) Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc. Natl. Acad. Sci. USA, 108, 632-637.
37. Zhang, Q., Spears, E., Boone, D.N., Li, Z., Gregory, M.A. and Hann, S.R. (2013) Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity. Proc. Natl. Acad. Sci. USA, 110, 978-983.
38. Chen, L., Wang, S., Zhou, Y., Wu, X., Entin, I., Epstein, J., Yaccoby, S., Xiong, W., Barlogie, B., Shaughnessy, J.D. Jr et al. (2010) Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood, 115, 61-70.
39. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., Sedivy, J.M., Kinzler, K.W. and Vogelstein, B. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science, 282, 1497-1501.
40. Consortium, E.P., Bernstein, B.E., Birney, E., Dunham, I., Green, E.D., Gunter, C. and Snyder, M. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57-74.
41. Fernandez, P.C., Frank, S.R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A. and Amati, B. (2003) Genomic targets of the human c-Myc protein. Genes Dev., 17, 1115-1129.
42. Guccione, E., Martinato, F., Finocchiaro, G., Luzi, L., Tizzoni, L., Olio, V., Zardo, G., Nervi, C., Bernard, L. and Amati, B. (2006) Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol., 8, 764-770.
43. Kim, J., Chu, J., Shen, X., Wang, J. and Orkin, S.H. (2008) An extended transcriptional network for pluripotency of embryonic stem cells. Cell, 132, 1049-1061.
44. Perna, D., Faga, G., Verrecchia, A., Gorski, M.M., Barozzi, I., Narang, V., Khng, J., Lim, K.C., Sung, W.K., Sanges, R. et al. (2011) Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene, 31, 1695-709.
45. Elkon, R., Zeller, K.I., Linhart, C., Dang, C.V., Shamir, R. and Shiloh, Y. (2004) In silico identification of transcriptional regulators associated with c-Myc. Nucleic Acids Res., 32, 4955-4961.
46. Dittmer, J. (2003) The biology of the Ets1 proto-oncogene. Mol. Cancer, 2, 2-29.
47. Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, C.M., Penn, L.Z. and Hancock, D.C. (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69, 119-128.
48. Pelengaris, S., Khan, M. and Evan, G.I. (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell, 109, 321-334.
49. Murphy, D.J., Junttila, M.R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D.A., Brown-Swigart, L., Johnson, L. and Evan, G.I. (2008) Distinct thresholds govern Myc's biological output in vivo. Cancer Cell, 14, 447-457.
50. Adachi, S., Obaya, A.J., Han, Z., Ramos-Desimone, N., Wyche, J.H. and Sedivy, J.M. (2001) c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle. Mol. Cell Biol., 21, 4929-4937.
51. Phesse, T.J., Myant, K.B., Cole, A.M., Ridgway, R.A., Pearson, H., Muncan, V., van den Brink, G.R., Vousden, K.H., Sears, R., Vassilev, L.T. et al. (2014) Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo. Cell Death Differ., 21, 956-966.
52. Hemann, M.T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J.A., Cordon-Cardo, C., Cleveland, J.L., Tansey, W.P. and Lowe, S.W. (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 436, 807-811.
53. Egle, A., Harris, A.W., Bouillet, P. and Cory, S. (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. USA, 101, 6164-6169.
54. Iaccarino, I., Hancock, D., Evan, G. and Downward, J. (2003) c-Myc induces cytochrome c release in Rat1 fibroblasts by increasing outer mitochondrial membrane permeability in a Bid-dependent manner. Cell Death Differ., 10, 599-608.
55. Busacca, S., Chacko, A.D., Klabatsa, A., Arthur, K., Sheaff, M., Gunasekharan, V.K., Gorski, J.J., El-Tanani, M., Broaddus, V.C., Gaudino, G. et al. (2013) BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. PLoS One, 8, e65489.
56. Dansen, T.B., Whitfield, J., Rostker, F., Brown-Swigart, L. and Evan, G.I. (2006) Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression in vivo. J. Biol. Chem., 281, 10890-10895.
57. Juin, P., Hunt, A., Littlewood, T., Griffiths, B., Swigart, L.B., Korsmeyer, S. and Evan, G. (2002) c-Myc functionally cooperates with Bax to induce apoptosis. Mol. Cell Biol., 22, 6158-6169.
58. Chen, S., Blank, J.L., Peters, T., Liu, X.J., Rappoli, D.M., Pickard, M.D., Menon, S., Yu, J., Driscoll, D.L., Lingaraj, T. et al. (2010) Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res., 70, 4318-4326.
59. Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D.R., Tessarollo, L., Casellas, R. et al. (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell, 151, 68-79.
60. Lin, C.Y., Loven, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee, T.I. and Young, R.A. (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell, 151, 56-67.
61. Hermeking, H., Rago, C., Schuhmacher, M., Li, Q., Barrett, J.F., Obaya, A.J., O'Connell, B.C., Mateyak, M.K., Tam, W., Kohlhuber, F. et al. (2000) Identification of CDK4 as a target of c-MYC. Proc. Natl. Acad. Sci. USA, 97, 2229-2234.
62. Nilsson, J.A., Keller, U.B., Baudino, T.A., Yang, C., Norton, S., Old, J.A., Nilsson, L.M., Neale, G., Kramer, D.L., Porter, C.W. et al. (2005) Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell, 7, 433-444.
63. Rounbehler, R.J., Fallahi, M., Yang, C., Steeves, M.A., Li, W., Doherty, J.R., Schaub, F.X., Sanduja, S., Dixon, D.A., Blackshear, P.J. et al. (2012) Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell, 150, 563-574.
64. Sabo, A., Kress, T.R., Pelizzola, M., de Pretis, S., Gorski, M.M., Tesi, A., Morelli, M.J., Bora, P., Doni, M., Verrecchia, A. et al. (2014) Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature, 511, 488-492.
65. Blackwell, T.K., Huang, J., Ma, A., Kretzner, L., Alt, F.W., Eisenman, R.N. and Weintraub, H. (1993) Binding of myc proteins to canonical and noncanonical DNA sequences. Mol. Cell Biol., 13, 5216-5224.
66. Zeller, K.I., Jegga, A.G., Aronow, B.J., O'Donnell, K.A. and Dang, C.V. (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol., 4, R69.
67. Kim, J., Lee, J.H. and Iyer, V.R. (2008) Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One, 3, e1798.
68. Zeller, K.I., Zhao, X., Lee, C.W., Chiu, K.P., Yao, F., Yustein, J.T., Ooi, H.S., Orlov, Y.L., Shahab, A., Yong, H.C. et al. (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc. Natl. Acad. Sci. USA, 103, 17834-17839.
69. Fernandez, Y., Verhaegen, M., Miller, T.P., Rush, J.L., Steiner, P., Opipari, A.W. Jr, Lowe, S.W. and Soengas, M.S. (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res., 65, 6294-6304.
70. Xie, B., Wang, C., Zheng, Z., Song, B., Ma, C., Thiel, G. and Li, M. (2011) Egr-1 transactivates Bim gene expression to promote neuronal apoptosis. J. Neurosci., 31, 5032-5044.
71. Campone, M., Noel, B., Couriaud, C., Grau, M., Guillemin, Y., Gautier, F., Gouraud, W., Charbonnel, C., Campion, L., Jezequel, P. et al. (2011) c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol. Cancer, 10, 1-14.
72. Walz, S., Lorenzin, F., Morton, J., Wiese, K.E., von Eyss, B., Herold, S., Rycak, L., Dumay-Odelot, H., Karim, S., Bartkuhn, M. et al. (2014) Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature, 511, 483-487.
73. Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N. and Sander, C. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat. Genet., 45, 1127-1133.
74. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J. et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 483, 570-575.
75. Sabo, A. and Amati, B. (2014) Genome recognition by MYC. Cold Spring Harbor Perspect. Med., 4, 2-4.
76. Thiel, G. and Cibelli, G. (2002) Regulation of life and death by the zinc finger transcription factor Egr-1. J. Cell Physiol., 193, 287-292.
77. Herold, S., Wanzel, M., Beuger, V., Frohme, C., Beul, D., Hillukkala, T., Syvaoja, J., Saluz, H.P., Haenel, F. and Eilers, M. (2002) Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell, 10, 509-521.
78. Conacci-Sorrell, M., McFerrin, L. and Eisenman, R.N. (2014) An overview of MYC and its interactome. Cold Spring Harbor Persp. Med., 4, a014357.
79. James, L. and Eisenman, R.N. (2002) Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo. Proc. Natl. Acad. Sci. USA, 99, 10429-10434.
80. Patel, J.H. and McMahon, S.B. (2006) Targeting of Miz-1 is essential for Myc-mediated apoptosis. J. Biol. Chem., 281, 3283-3289.
81. Amati, B., Littlewood, T.D., Evan, G.I. and Land, H. (1993) The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J., 12, 5083-5087.